Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77.3M
-
Number of holders
-
213
-
Total 13F shares, excl. options
-
84.3M
-
Shares change
-
+934K
-
Total reported value, excl. options
-
$3.39B
-
Value change
-
+$52.6M
-
Put/Call ratio
-
1.31
-
Number of buys
-
97
-
Number of sells
-
-90
-
Price
-
$40.15
Significant Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q3 2025
244 filings reported holding XENE - Xenon Pharmaceuticals Inc. - Common Stock as of Q3 2025.
Xenon Pharmaceuticals Inc. - Common Stock (XENE) has 213 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 84.3M shares
.
Largest 10 shareholders include FMR LLC (8.92M shares), Avoro Capital Advisors LLC (5.4M shares), BlackRock, Inc. (4.77M shares), Driehaus Capital Management LLC (4.17M shares), JANUS HENDERSON GROUP PLC (3.94M shares), WELLINGTON MANAGEMENT GROUP LLP (3.61M shares), BRAIDWELL LP (3.61M shares), Capital International Investors (3.18M shares), Commodore Capital LP (2.7M shares), and Polar Capital Holdings Plc (2.55M shares).
This table shows the top 213 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.